ASTELLAS AND AUDAX BIOSCIENCES ENTER EXCLUSIVE OPTION AND LICENSE AGREEMENT FOR DAX-044, A NOVEL IMMUNE-TARGETED IL-12 ANTIBODY-CYTOKINE FUSION FOR IMMUNO-ONCOLOGY

Reuters · 4d ago

Please log in to view news